U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H19FN4O2
Molecular Weight 390.4103
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of TUCIDINOSTAT

SMILES

NC1=CC(F)=CC=C1NC(=O)C2=CC=C(CNC(=O)\C=C\C3=CC=CN=C3)C=C2

InChI

InChIKey=SZMJVTADHFNAIS-BJMVGYQFSA-N
InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+

HIDE SMILES / InChI

Molecular Formula C22H19FN4O2
Molecular Weight 390.4103
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Chidamide (CS055) is a novel and orally active benzamide class of histone deacetylase (HDAC) inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, the enzymes that are involved and play an important role in tumor initiation and development in both tumor cells and their surrounding micro-environment. It was approved by the CFDA in December 2014 for the treatment of recurrent of refractory peripheral T-cell lymphoma. Reported hematological adverse events are: neutropenia, thrombocytopenia, leukopenia. Chidamide is under investigation as a potential agent for the treatment of other types of tumors.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.095 µM [IC50]
0.16 µM [IC50]
0.067 µM [IC50]
0.733 µM [IC50]
0.078 µM [IC50]
0.432 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Epidaza

Approved Use

Epidaza tablets are indicated for patients with recurrent or refractory peripheral T-cell lymphoma (PTCL) who have received at least one systemic chemotherapy.

Launch Date

2012
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Chidamide tablets: HDAC inhibition to treat lymphoma.
2017 Mar
Patents

Sample Use Guides

30 mg (6 tablets) twice a week. The interval should not be less than 3 days, 30 min after breakfast.
Route of Administration: Oral
At low concentrations (<1 uM), Chidamide induced G1 arrest in human leukaemia cell lines and primary myeloid leukaemia cells. At moderate concentrations (0.5 uM-2 uM), Chidamide induced differentiation, as determined by the increased expression of the myeloid differentiation marker CD11b. At relatively high concentrations (2 uM-4 uM), Chidamide potently induced caspase-dependent apoptosis.
Substance Class Chemical
Created
by admin
on Sat Dec 16 07:49:13 GMT 2023
Edited
by admin
on Sat Dec 16 07:49:13 GMT 2023
Record UNII
87CIC980Y0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TUCIDINOSTAT
INN   USAN  
INN   USAN  
Official Name English
EPIDAZA
Brand Name English
Tucidinostat [WHO-DD]
Common Name English
Chidamide [WHO-DD]
Common Name English
tucidinostat [INN]
Common Name English
N-(2-AMINO-4-FLUOROPHENYL)-4-(((2E)-3-(PYRIDIN-3-YL)PROP- 2-ENAMIDO)METHYL)BENZAMIDE
Systematic Name English
CS055
Code English
TUCIDINOSTAT [JAN]
Common Name English
N-(2-AMINO-4-FLUOROPHENYL)-4-(((1-OXO-3-(3-PYRIDINYL)-2-PROPEN-1-YL)AMINO)METHYL)BENZAMIDE
Systematic Name English
CS-055
Code English
BENZAMIDE, N-(2-AMINO-4-FLUOROPHENYL)-4-((((2E)-1-OXO-3-(3-PYRIDINYL)-2-PROPEN-1-YL)AMINO)METHYL)-
Systematic Name English
CHIDAMIDE
WHO-DD  
Common Name English
BENZAMIDE, N-(2-AMINO-4-FLUOROPHENYL)-4-(((1-OXO-3-(3-PYRIDINYL)-2-PROPEN-1-YL)AMINO)METHYL)-
Systematic Name English
TUCIDINOSTAT [USAN]
Common Name English
HBI-8000
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 867121
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
NCI_THESAURUS C1946
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
Code System Code Type Description
IUPHAR
8305
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
PUBCHEM
12136798
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
WIKIPEDIA
CHIDAMIDE
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
DRUG BANK
DB06334
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
FDA UNII
87CIC980Y0
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
CAS
1616493-44-7
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
CAS
743438-44-0
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
NON-SPECIFIC STEREOCHEMISTRY
EPA CompTox
DTXSID701032295
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
USAN
DE-60
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
INN
10318
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
SMS_ID
100000170195
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
DRUG CENTRAL
4973
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
EVMPD
SUB184005
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
NCI_THESAURUS
C97263
Created by admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
PRIMARY
Related Record Type Details
TARGET->WEAK INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY